Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Bill and Melinda Gates Foundation | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators hypothesize that schoolchildren treated with IPT using DP over one year of follow-up will have a different risk of clinical malaria compared to those treated with placebo.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Four monthly IPT | Experimental | IPT give once a school term (every four months) |
|
| Monthly IPT | Experimental | IPT given every month |
|
| Placebo | Placebo Comparator | No active drug in the placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Four monthly IPT with dihydroartemisinin Piperaquine (DP) | Drug | Given every 4 months (once a school term) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Risk of Clinical Malaria | Fever(temperature greater or equal to 37.5 degrees centigrade or history of fever in past 24 hours) in presence of parasitemia. | 1 year |
| Cognitive function tests | Mean score in the cognitive function tests (Raven's Matrices test and Code transmission test) | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Risk of parasitemia | presence of asexual parasites on blood smear | 1 year |
| Risk of hospital admissions | Admission of any cause | 1 year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Joaniter I Nankabirwa, MSc CEB | Makerere University Kampala | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mulanda Sub-district | Tororo | Uganda | 256 | Uganda |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27401569 | Derived | Nankabirwa JI, Conrad MD, Legac J, Tukwasibwe S, Tumwebaze P, Wandera B, Brooker SJ, Staedke SG, Kamya MR, Nsobya SL, Dorsey G, Rosenthal PJ. Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine in Ugandan Schoolchildren Selects for Plasmodium falciparum Transporter Polymorphisms That Modify Drug Sensitivity. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5649-54. doi: 10.1128/AAC.00920-16. Print 2016 Oct. | |
| 24621953 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008288 | Malaria |
| ID | Term |
|---|---|
| D011528 | Protozoan Infections |
| D010272 | Parasitic Diseases |
| D007239 | Infections |
| D000096724 | Mosquito-Borne Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Monthly IPT using DP | Drug | Given every month |
|
|
| Placebo given every month | Drug | No active ingredient |
|
|
| Risk of adverse events | Any untoward medical occurrence in a participant taking study medication | 1 year |
| School performance | Average position in class as reported in the end of the year school report | 1 year |
| Prevalence of anemia | Proportion of hemoglobin measurements < 10 g/dL. | 1 year |
| Derived |
| Nankabirwa JI, Wandera B, Amuge P, Kiwanuka N, Dorsey G, Rosenthal PJ, Brooker SJ, Staedke SG, Kamya MR. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis. 2014 May;58(10):1404-12. doi: 10.1093/cid/ciu150. Epub 2014 Mar 12. |
| D000079426 |
| Vector Borne Diseases |